Guangdong Zhonghao Pharmaceutical

Guangdong Zhonghao Pharmaceutical has successfully developed and commercialized at least one major new drug, benvitimod, an AHR agonist for moderate atopic dermatitis, which reached Phase 3 and was first approved in China on May 29, 2019[1][3].

The company operates as a pharmaceutical manufacturer with a focus on innovative drug development and production. It has contributed to the growth of the health and pharmaceutical industry cluster in Zhongshan/NHTP park[3].

It is a subsidiary of Guanhao Biotech.

No detailed clinical trial results are available from the provided sources.

The pipeline breadth appears limited based on public data; only benvitimod can be confirmed as an advanced program[1].

There may be additional programs or products not captured by English-language sources.

The company’s manufacturing capabilities has enabled it to industrialize new drugs for market launch since at least October 2019[3].

No evidence of acquisition or closure; company appears active.

No evidence of public trading or stock symbol.

Key people, partnerships, revenue figures, investors etc. are not disclosed in available sources.